{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"data_sharing_plan":["IPD Sharing (as of January 2021): Yes\nDescription: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer’s data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.\nURL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"],"condition":["Metastatic Colorectal Cancer","Colorectal cancer metastatic","Cáncer colorrectal metastásico con RAS mutado o no mutado","Mutant RAS or wild-type (WT) RAS metastatic colorectal cancer","Colorectal Neoplasms","Colorectal neoplasms malignant","Colorectal cancer recurrent"],"disease":["Metastatic Colorectal Cancer","Cáncer Colorrectal Metastásico Con Ras Mutado O No Mutado","Mutant Ras Or Wild-type (wt) Ras Metastatic Colorectal Cancer","Colorectal Neoplasms Malignant","Colorectal Cancer Recurrent","Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2150444"],"location":["Canada","Netherlands","Belgium","United States","Italy","France","Germany","Spain"],"study_start_month":["11"],"keyword":["Wild-type RAS,","Panitumumab,","MEK162,","Adult mCRC patient","Panitumumab","Mutant RAS,","Metastatic colorectal cancer,","MEK162"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors","description":"The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.","dates":{"creation":"2013-11-15"},"accession":"2150444","cross_references":{"ClinicalTrials___gov":["NCT01927341"],"EU Clinical Trials Register":["2013-001986-18"]}}